Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-071930
Filing Date
2025-05-15
Accepted
2025-05-15 06:18:37
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8633
2 EX-99.A ck0001669811-ex99_a.pdf EX-99.A 113368
3 EX-99.B ck0001669811-ex99_b.pdf EX-99.B 56026
  Complete submission text file 0000950170-25-071930.txt   244190
Mailing Address 50 MARTIN PLACE SYDNEY, NSW 2000 C3 2000
Business Address 50 MARTIN PLACE SYDNEY, NSW 2000 C3 2000 212.231.1000
MACQUARIE GROUP LTD (Filed by) CIK: 0001418333 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Subject) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87088 | Film No.: 25948463
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)